APA (7th ed.) Citation

Schneider, D., Brandt, T., & Hacke, W. (1998). Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): An open-label, dose escalation study in patients hospitalized for acute stroke. European neurology, 40(2), . https://doi.org/10.1159/000007962

Chicago Style (17th ed.) Citation

Schneider, Dietmar, Tobias Brandt, and Werner Hacke. "Safety, Pharmacokinetics and Biological Activity of Enlimomab (anti-ICAM-1 Antibody): An Open-label, Dose Escalation Study in Patients Hospitalized for Acute Stroke." European Neurology 40, no. 2 (1998). https://doi.org/10.1159/000007962.

MLA (9th ed.) Citation

Schneider, Dietmar, et al. "Safety, Pharmacokinetics and Biological Activity of Enlimomab (anti-ICAM-1 Antibody): An Open-label, Dose Escalation Study in Patients Hospitalized for Acute Stroke." European Neurology, vol. 40, no. 2, 1998, https://doi.org/10.1159/000007962.